Pierre Emmanuel Morange
Overview
Explore the profile of Pierre Emmanuel Morange including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de la Morena-Barrio M, Suchon P, Jacobsen E, Iversen N, Minano A, de la Morena-Barrio B, et al.
Blood
. 2022 Apr;
140(2):140-151.
PMID: 35486842
Antithrombin deficiency, the most severe congenital thrombophilia, might be underestimated, as some pathogenic variants are not detected by routine functional methods. We have identified 2 new SERPINC1 variants, p.Glu227Lys and...
2.
Deharo P, Quilici J, Camoin-Jau L, Johnson T, Bassez C, Bonnet G, et al.
JACC Cardiovasc Interv
. 2017 Dec;
10(24):2560-2570.
PMID: 29268886
Objectives: This study sought to evaluate the impact of initial platelet reactivity on the benefit of switched strategy. Background: TOPIC (Timing Of Platelet Inhibition after acute Coronary Syndrome) study suggested...
3.
Cuisset T, Deharo P, Quilici J, Johnson T, Deffarges S, Bassez C, et al.
Eur Heart J
. 2017 May;
38(41):3070-3078.
PMID: 28510646
Aims: Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant ischaemic benefit over clopidogrel after acute coronary syndrome (ACS). However, both drugs are associated with an increase in bleeding complications. The...
4.
Saultier P, Vidal L, Canault M, Bernot D, Falaise C, Pouymayou C, et al.
Haematologica
. 2017 Mar;
102(6):1006-1016.
PMID: 28255014
Congenital macrothrombocytopenia is a family of rare diseases, of which a significant fraction remains to be genetically characterized. To analyze cases of unexplained thrombocytopenia, 27 individuals from a patient cohort...
5.
Poggi M, Canault M, Favier M, Turro E, Saultier P, Ghalloussi D, et al.
Haematologica
. 2016 Sep;
102(2):282-294.
PMID: 27663637
Variants in ETV6, which encodes a transcription repressor of the E26 transformation-specific family, have recently been reported to be responsible for inherited thrombocytopenia and hematologic malignancy. We sequenced the DNA...
6.
Shahabi P, Cuisset T, Stathopoulou M, Morange P, Grosdidier C, Herbeth B, et al.
Pharmacogenomics
. 2015 Apr;
16(5):459-69.
PMID: 25916518
Aim: To investigate whether the interactions of CYP2C19*2 and CYP2C19*17 with smoking are associated with the levels of P2Y12 receptor inhibition and CRP, in on-thienopyridine post-stenting patients. Methods & Results:...
7.
Pankert M, Quilici J, Loundou A, Verdier V, Lambert M, Deharo P, et al.
Am J Cardiol
. 2013 Nov;
113(1):54-9.
PMID: 24182762
This study aimed to analyze the impact of body mass index (BMI) and the metabolic syndrome (MS) on responses to clopidogrel or prasugrel and bleeding risk after acute coronary syndrome....
8.
Cuisset T, Grosdidier C, Loundou A, Quilici J, Loosveld M, Camoin L, et al.
JACC Cardiovasc Interv
. 2013 Aug;
6(8):854-63.
PMID: 23968703
Objectives: This study was designed to define the hyperresponse to thienopyridine (very low on-treatment platelet reactivity [VLTPR]) as the most predictive threshold value of platelet reactivity index vasodilator-stimulated phosphoprotein (PRI...
9.
Quilici J, Fugon L, Beguin S, Morange P, Bonnet J, Alessi M, et al.
Int J Cardiol
. 2013 Mar;
168(1):568-9.
PMID: 23462636
No abstract available.
10.
Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro P, Saut N, et al.
Am J Cardiol
. 2013 Jan;
111(7):985-90.
PMID: 23340030
The present study was performed to compare the influence of cytochrome P459 2C19 (CYP2C19) *2 and *17 genetic variants on the platelet response to clopidogrel and prasugrel maintenance therapy and...